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Key Points 
• In 2018, the European Working Group on Sarcopenia in Older people established a new 
operational definition and new cut-off points for sarcopenia (EWGSOP2). This new guideline 
suggests that low muscle strength more than low muscle mass is the principal determinant of 
sarcopenia. 
• We identified that the EWGSOP2 recognised fewer people as having sarcopenia and the people 
identified were not at risk of as many adverse health outcomes as those identified using the 
previous definition. 
• Caution needs to be taken with those individuals who are not any longer sarcopenic using the 
new classification but still have a higher risk of adverse health outcomes.  
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Abstract 
Introduction- Recently, the European Working Group on Sarcopenia in Older People (EWGSOP) 
established a new operational definition and cut-off points for sarcopenia. The aim of this study was, 
therefore, to compare the prevalence of sarcopenia and its associations with different health outcome 
using the old (EWGSOP1) and new (EWGSOP2) definitions of sarcopenia in the UK Biobank cohort.    
Methods- Sarcopenia was defined as low grip strength plus low muscle mass. Using both EWGSOP 
cut-off points, we created specific sarcopenia variables. Prevalence of sarcopenia derived using both 
EWGSOP definitions were calculated and compared as well as prospective health outcomes including 
all-cause mortality as well as incidence and mortality from cardiovascular disease (CVD), respiratory 
disease, and chronic obstructive pulmonary disease (COPD).  
Results- The prevalence of sarcopenia based on the EWGSOP1 and EWGSOP2 classification were 
8.14% and 0.36%, respectively. Sarcopenia defined by EWGSOP1 was associated with a higher risk of 
respiratory disease and COPD as well as mortality from all-cause, CVD, and respiratory diseases. 
However, only respiratory incidence remained associated with sarcopenia when EWGSOP2 was used 
(HR: 1.32 [95% CI: 1.05 to 1.66]). Moreover, although individuals classified as sarcopenic using both 
classifications had the highest risk of all-cause mortality and respiratory disease, those with sarcopenia 
based on EWGSOP1 only experienced a more extensive range of poorer health outcomes.   
Conclusion- In comparison with EWGSOP1, the new classification (EWGSOP2) produced a lower 
estimate of sarcopenia prevalence and fewer associations with adverse health outcomes. Although 
these associations were higher, many become not-significant.  
Keywords: sarcopenia; mortality; incidence; muscle strength; EWGSOP 
  
Introduction  
Sarcopenia is a syndrome characterised by a progressive loss of muscle quantity and quality, which 
results in an increased risk of falls, fractures, hospitalisation, morbidity/mortality and reduces the 
quality of life [1]. This leads to a worse outcome in both elderly and middle-aged adults and with a 
higher economic burden and health care cost (~£2.5 billion/year in the UK) [2]. Different operational 
definitions have been proposed to defined sarcopenia, most based on the combination of three 
primary physical capability markers: low muscle mass, low grip strength and slow gait speed [3-7]. In 
2010, the European Working Group on Sarcopenia in Older People (EWGSOP1) defined sarcopenia as 
the combination of low muscle mass and either low grip strength or slow gait speed [3]. Recently, the 
EWGSOP established a new operational definition and new cut-off points for sarcopenia 
(EWGSOP2)[8]. This new guideline suggests that low grip strength more than low muscle mass is the 
principal determinant of sarcopenia, thereby, the definition of sarcopenia requires both low grip 
strength and low muscle mass with the addition of slow gait speed being used to define severe 
sarcopenia.  
Although experts in the field have accepted used this new sarcopenia guideline, concern has been 
expressed regarding its effect on the prevalence and outcomes of sarcopenia [9-13]. The aim of this 
study was, therefore, to compare the prevalence of sarcopenia and its associations with different 
health outcome using the old (EWGSOP1) and new (EWGSOP2) definitions of sarcopenia in the UK 
Biobank cohort.    
Methods 
To compare both classifications according to each EWGSOP guidelines (EGWSOP1 and EWGSOP2), 
sarcopenia was defined as low grip strength plus low muscle mass. Following both EWGSOP cut-off 
points (2010 and 2019), we create specific sarcopenia variables (Supplementary Figure 2a and 2b). 
More details about Uk Biobank, other procedures, sarcopenia classification and other variables are 
available in supplementary methods. 
Statistical analyses 
Associations between sarcopenia and health outcomes, by EWGSOP1 and EWGSOP2 criteria, were 
investigated using Cox-proportional hazard models using STATA 14 statistical software (StataCorp LP). 
The results are reported as hazard ratios (HR) and their 95% confidence intervals (95% CI).  
Moreover, to investigate differences in the association of sarcopenia with health outcomes according 
to EWGSOP1 and EWGSOP2, we derived the following categories: “Always no sarcopenia” (individuals 
classified as normal in both EWGSOP1 and EWGSOP2). “Sarcopenia-EWGSOP1” (include individual 
classified as sarcopenic following the EWGSOP1). Finally, “Sarcopenia” (include individuals who were 
classified as sarcopenic in both definitions EWGSOP1 and EWGSOP2) (Supplementary Figure 2c).  
More details about statistical analyses are available in supplementary methods.  
Results  
The general characteristics of the population using the old (EWGSOP1) and new (EWGSOP2) 
classifications are presented in Supplementary Figure 1 and Supplementary Table 1. Overall, the 
prevalence of sarcopenia was lower when EWGSOP2 was used in comparison to EWGSOP1 (0.36% vs 
8.14%); however, the mean age was higher (63.0 versus 60.7 years). With increasing age, the relative 
differences between the two classifications decreased, but the absolute differences increased (<54 
years: 3.98 and 0.09; 54-61 years: 9.67 and 0.41; >61 years: 14.9 and 0.93 in EWGSOP1 and EWGSOP2, 
respectively). In terms of sex, the prevalence of sarcopenia was higher in women than in men. 
Changing from the old to the new classification, reduced the prevalence of overweight, obesity, 
central obesity, diabetes, cardiovascular disease (CVD) and high blood pressure but increased the 
prevalence of falls and fractures among people defined as sarcopenic (Supplementary Table 1).  
The associations between sarcopenia and health outcomes using both definitions are presented in 
Table 1. Individuals with sarcopenia defined by EWGSOP1 had a higher risk than individuals with no 
sarcopenia of all-cause (HR: 1.16 [95% CI: 1.09 to 1.25]), CVD (HR: 1.30 [95% CI: 1.10 to 1.54]), and 
respiratory disease (HR: 1.19 [95% CI 1.01 to 1.41]) mortality. They also had a higher risk of incident 
respiratory disease (HR: 1.11 [95% CI: 1.02 to 1.16]) and COPD (HR: 1.38 [95% CI: 1.12 to 1.67]). When 
the new classification for defining sarcopenia was used, only respiratory disease incidence remained 
associated with sarcopenia (HR: 1.32 [95% CI: 1.05 to 1.66]). No associations were found for COPD 
incidence and mortality from all-cause, CVD and respiratory diseases.  
Differences in the associations with health outcomes using the new and old classifications are 
presented in Figure 2. Compared to those who were classified as no sarcopenia according to both 
EWGSOP1 and EWGSOP2 definitions (“always no sarcopenia”), individuals who were classified as 
having “always-sarcopenia” had the highest increased risk of all-cause mortality (HR: 1.29 [95% CI: 
1.02 to 1.64]) and respiratory disease incidence (HR: 1.35 [95% CI: 1.07 to 1.70]). Nevertheless, those 
who were classified as sarcopenic only according to the EWGSOP1 definition (“sarcopenia EWGSOP1”) 
had increased risk of a more significant number of health outcomes (incident respiratory disease and 
COPD as well as all-cause and CVD mortality). 
Discussion  
It is already known than sarcopenia leads to a worse health outcome. Consequently, early detection 
and intervention are essential to reduce frailty, falls, functional, cognitive impairments, cardiovascular 
disease and mortality [1, 8]. In this study, the key finding was that the new EWGSOP2 definition 
identifies fewer people as having sarcopenia and the people identified were not at risk of as many 
adverse health outcomes as those identified using the previous definition. As a result, one of the main 
implications of using the new definition may be not to identify people who remain at risk of adverse 
health outcomes, since the numbers of people with diagnose of sarcopenia decrease substantially 
using this new definition. However, it is also important to highlight that although the associations 
using the new classifications were not significant, were higher than using the EWGSOP1. Therefore, 
our findings suggest that further work in this area would be essential.  
Except for one study [14], there has been consistent evidence that using the new EWGSOP2 definition 
produces a lower prevalence estimate in comparison to the EWGSOP1 definition [9-13]. However, our 
findings show that under the new EWGSOP2 definition, the relative prevalence of sarcopenia almost 
disappeared (~0.4%). One explanation for these differences could be the average age of the UK 
Biobank population with sarcopenia (60.7 and 63.0 years, according to EWGSOP1 and EWGSOP2, 
respectively), i.e., a still adult population. In this context, and although the development of sarcopenia 
starts during adult life [15],  the prevalence of sarcopenia using the new definition could be higher in 
an older population. 
The associations between the previous classification of sarcopenia (EWGSOP1) and adverse health 
outcomes have been widely studied [16-18]. However, considering that the new definition (EWGSOP2) 
was just published at the end of last year [19] and amended in May of this year [8], fewer studies have 
investigated its association with health outcomes [11, 14]. Locquet et al. reported that the new 
EWGSOP2 was not significantly associated with all-cause mortality in contrast to their previous results 
using the EWGSOP1 (HR: 2.74 [95% CI: 0.98 to 7.65] and HR: 2.93 [95% CI: 1.17 to 7.35], 
respectively)[11]. Dávalos-Yerovi et al. demonstrated that both classifications were associated with 
COPD mortality in the most adjusted model. However, once again, the EWGSOP1 association was 
stronger in comparison to the EWGSOP2 [14]. 
Considering that the new EWGSOP2 definition decreases the estimate prevalence of sarcopenia, it is 
expected that the number of events, and consequently the statistical power, were lower in the 
analysis using EWGSOP2 definition. Regardless of power, we did find that people categorised as 
sarcopenic per EWGSOP1 were of higher risk for multiple fatal and nonfatal outcomes (Table 1). This 
again highlights the relevance of the cut-off points used to define sarcopenia and how these could 
affect the association of this condition with different adverse health outcome. Therefore, caution 
needs to be taken with those individuals who are not any longer sarcopenic using the new 
classification but still have a higher risk. 
 
Strengths and limitations 
Using the UK Biobank study provided the opportunity to test our research question in a large general 
population cohort as well as the opportunity to work with information collected using validated and 
standardised methods. However, UK Biobank is not representative of the UK population in terms of 
lifestyle and prevalent disease [20]. Therefore, care needs to be heeded not to generalise the absolute 
prevalence. However, in contrast, the effect size estimates (HR) can be generalised beyond the study 
population. Finally, given the low prevalence of EWGSOP2 sarcopenia, the corresponding analysis is 
underpowered. Other limitations of this study are available in supplementary limitations. 
Conclusion  
Substantial changes in the estimate prevalence and association patterns were found between 
EWGSOP1 and EWGSOP2 definitions. Using the new operational guideline, the estimate prevalence of 
sarcopenia decreased considerably. 
Furthermore, although the new EGWSOP2 showed a higher magnitude of association with the health 
outcomes, many of the associations were non-significant due to the lower numbers of individuals 
meeting the new classification criteria. However, more research is needed to generate a valid and 
realisable definition for sarcopenia. This could help us to identify high-risk individuals in an early stage 
and, therefore, implement prevention programs aiming to maintain or increase physical capability 
markers related to sarcopenia.  
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Table 1. Association of mortality and incidence health outcomes using EWGSOP1 and EWGSOP2 
definitions.    
 
Data presented as adjusted hazard ratio (HR) and its 95% confidence interval (95%CI) by sarcopenia EWGSOP1 and 
EWGSOP2. Normal people were used as the reference group for the analysis. All analyses were conducted using a 2-years 
landmark analyses and by excluding participant with major diseases at baseline.  Model was adjusted by age, sex, gross 
income, education attainment, smoking, sleep duration, BMI, physical activity, total discretionary sedentary time, dietary 
intake (including alcohol, fruit and vegetable, oily fish, red meat and processed meat intake) and illnesses (hypertension, 
diabetes, depression, CVD, and cancer). 
 
 
  
 No sarcopenia (normal) Sarcopenia 
 Total n /events         HR (95%CI) Total n /events HR (95% CI) p-value 
All-cause mortality      
EWGSOP1 199,972 / 5,121 1.00 (Ref.) 35,221 / 1,419 1.16 (1.09; 1.25) <0.001 
EWGSOP2 358,994 / 10,081 1.00 (Ref.) 1,519 / 72 1.25 (0.99; 1.58) 0.059 
CVD mortality       
EWGSOP1 195,082 / 832 1.00 (Ref.) 34,250 / 227 1.30 (1.10; 1.54) 0.002 
EWGSOP2 350,405 / 1,558 1.00 (Ref.) 1,468 / 8 1.21 (0.60; 2.44) 0.588 
Respiratory Mortality       
EWGSOP1 198,693 / 731 1.00 (Ref.) 34,702 / 253 1.19 (1.01; 1.41) 0.042 
EWGSOP2 356,171 / 1,571 1.00 (Ref.) 1,474 / 15 1.53 (0.91; 2.56) 0.108 
CVD incidence      
EWGSOP1 192,907 / 8,166 1.00 (Ref.) 33,848 / 1,556 1.05 (0.99; 1.12) 0.078 
EWGSOP2 346,371 / 14,812 1.00 (Ref.) 1,446 / 67 1.11 (0.87; 1.41) 0.400 
Respiratory incidence      
EWGSOP1 197,349 / 6,098 1.00 (Ref.) 34,377 / 1,419 1.11 (1.04; 1.19) 0.001 
EWGSOP2 353,645 / 11,459 1.00 (Ref.) 1,457 / 76 1.32 (1.05; 1.66) 0.017 
COPD incidence      
EWGSOP1 198,707 / 383 1.00 (Ref.) 34,709 / 145 1.38 (1.10; 1.74) 0.005 
EWGSOP2 356,227 / 821  1.00 (Ref.) 1,476 / 10 1.76 (0.93; 3.31) 0.083 
 1 
Figure 1.  Association of mortality and incidence health outcomes with sarcopenia classifications 2 
from EWGSOP1 and EGSOP2. 3 
Data presented as adjusted hazard ratio (HR) and its 95% confidence interval (95%CI) by sarcopenia categories. Sarcopenia 4 
classifications: always no sarcopenia: individuals classified as normal in both EWGSOP1 and EWGSOP2; Sarcopenia-5 
EWGSOP1: include individual classified as sarcopenic following the EWGSOP1; Sarcopenia: include individuals who were 6 
classified as sarcopenic in both definitions EWGSOP1 and EWGSOP2. Always no sarcopenia people were used as the 7 
reference group for the analysis. All analyses were conducted using a 2-years landmark analyses and by excluding participant 8 
with major diseases at baseline. Model was adjusted by age, sex, gross income, education attainment, smoking, sleep 9 
duration, BMI, physical activity, total discretionary sedentary time, dietary intake (including alcohol, fruit and vegetable, oily 10 
fish, red meat and processed meat intake) and illnesses (hypertension, diabetes, depression, CVD, and cancer). 11 
